Same statement from Insmed for the past 9 years re:Oncology
Oncology Programs rhIGFBP-3 is in early clinical development and could be primarily investigated for the treatment of cancer. We believe rhIGFBP-3 is a promising potential novel treatment for a variety of cancer types. Preclinical models demonstrate that both treatments interact with the IGF system to reduce tumor growth. We are not actively pursuing the development of either of these products at this time.